| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Rikshospitalet-Radiumhospitalet HF |
| Information provided by: | Rikshospitalet-Radiumhospitalet HF |
| ClinicalTrials.gov Identifier: | NCT00257751 |
Purpose
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI. An increasing number of patients are referred to emergent or urgent CABG, and several studies, as well as our own experience, have shown that preoperative administration of irreversible platelets inhibitors increase the risk of bleeding complications following CABG.
| Condition | Intervention |
|
Coronary Artery Disease |
Procedure: Aprotinine |
| MedlinePlus related topics: | Coronary Artery Disease |
| ChemIDplus related topics: | Aprotinin Clopidogrel Clopidogrel Bisulfate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Efficacy Study |
| Official Title: | Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving |
| Estimated Enrollment: | 400 |
| Study Start Date: | March 2004 |
| Estimated Study Completion Date: | March 2007 |
Aprotinine (Trasylol) is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery. The most commeon practice is to give Trasylol in high doses immediately before surgery, during the operation, and during the first postoperative hours. However, it has also been shown that there is a hemostatic effect of the drug when given in a lower dose postoperatively, but this remains unclear.
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
All coronary bypass operations in patients receiving Plavix within the last 7 days
Contacts and Locations| Contact: Eivind Øvrum, MD, PhD | +4722866500 | eivind.ovrum@hjertesenteret.no |
| Norway | |||||
| RRHF | Recruiting | ||||
| Oslo, Norway, 0027 | |||||
| Contact: Eivind Øvrum, MD, PhD +4722866500 eivind.ovrum@hjertesenteret.no | |||||
| Rikshospitalet-Radiumhospitalet HF |
| Principal Investigator: | Eivind Øvrum, MD, PhD | Rikshospitalet-Radiumhospitalet HF |
More Information
| Study ID Numbers: | APROT04, APROT04 |
| First Received: | November 22, 2005 |
| Last Updated: | November 22, 2005 |
| ClinicalTrials.gov Identifier: | NCT00257751 |
| Health Authority: | Norway: Norwegian Medicines Agency; Norway:The Data Inspectorate; Norway: Directorate for Health and Social Affairs |
|
|
|
|
